This can help more people get the care they need
Wegovy (semaglutide) tablets are a prescription medicine used with a reduced-calorie diet and increased physical activity to: reduce the risk of major cardiovascular events such as death, heart attack, or stroke in adults with known heart disease and with either obesity or overweight
In addition to its use in diabetes management, semaglutide has also been FDA-approved for weight loss in individuals with obesity
Retrieved from Rubino, D., Abrahamsson, N., Davies, M., et al
Key points The choice of preclinical models should align with the current steatotic liver disease definition: cardiometabolic risk factors must be appropriately recapitulated to place metabolic dysfunction-associated steatotic liver disease (MASLD) and metabolic dysfunction-associated steatohepatitis (MASH)-related hepatocellular carcinoma (HCC) models in the right metabolic context